Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 11/20 | 0.42 |
| ▸ | NPC1 | O15118 | 10/20 | 0.42 |
| ▸ | GFER | P55789 | 3/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4150810 | 0.83 | KDM4E (0.42) | RAB9ANPC1GFERRXFP1MEN1 | |
| SCHEMBL207265 | 0.75 | AHR (0.37) | RAB9ANPC1MEN1KMT2AHTT | |
| SCHEMBL940594 | 0.72 | ALDH1A1 (0.44) | RAB9ANPC1MEN1KMT2ALMNA | |
| SCHEMBL7278572 | 0.72 | HTR1A (0.41) | KMT2AHTR1ASMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL407727 | 0.71 | PKM (0.45) | RAB9AMEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL6411255 | 0.71 | NPC1 (0.36) | RAB9ANPC1GFERMEN1KMT2A | |
| SCHEMBL3856893 | 0.69 | TDP1 (0.43) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3746355 | 0.67 | NQO2 (0.43) | RAB9ANPC1LMNAACHESMN1; SMN2 | |
| SCHEMBL3028409 | 0.66 | NPC1 (0.37) | RAB9ANPC1MEN1KMT2ALMNA | |
| SCHEMBL5331382 | 0.65 | AHR (0.36) | RAB9ANPC1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158025-A1 | GALACTOKINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH | 2023-05-25 | — | — | US | claimed |
| WO-2021216812-A1 | GALACTOKINASE INHIBITORS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2021-10-28 | — | — | WO | claimed |
| US-20090136448-A1 | Antiviral 2-Carboxy-Thiophene Compounds | CORFIELD JOHN ANDREW | 2009-05-28 | — | — | US | claimed |
| WO-2009000818-A1 | 3-CARBONYLAMINOTHIOPHENE-2-CARBOXYLIC ACIDS AS HEPATITIS C VIRUS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-31 | — | — | WO | claimed |
| EP-1971599-A1 | ANTIVIRAL 2-CARBOXY-THIOPHENE COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-09-24 | — | — | EP | claimed |
| WO-2008043791-A2 | THIOPHENE DERIVATIVES FOR TREATING HEPATITIS C | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-17 | — | — | WO | claimed |
| WO-2008017688-A1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI-VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-14 | — | — | WO | claimed |
| WO-2007071434-A1 | ANTIVIRAL 2-CARBOXY-THIOPHENE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-28 | — | — | WO | claimed |
| US-20230158025-A1 | GALACTOKINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH | 2023-05-25 | — | — | US | disclosed |
| WO-2021216812-A1 | GALACTOKINASE INHIBITORS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2021-10-28 | — | — | WO | disclosed |
| CN-104204037-B | Polyamic acid and containing its resin combination | 东丽株式会社 | 2016-08-24 | — | — | CN | disclosed |
| US-20090136448-A1 | Antiviral 2-Carboxy-Thiophene Compounds | CORFIELD JOHN ANDREW | 2009-05-28 | — | — | US | disclosed |
| WO-2009000818-A1 | 3-CARBONYLAMINOTHIOPHENE-2-CARBOXYLIC ACIDS AS HEPATITIS C VIRUS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-31 | — | — | WO | disclosed |
| EP-1971599-A1 | ANTIVIRAL 2-CARBOXY-THIOPHENE COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-09-24 | — | — | EP | disclosed |
| WO-2008043791-A2 | THIOPHENE DERIVATIVES FOR TREATING HEPATITIS C | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008017688-A1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI-VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-14 | — | — | WO | disclosed |
| WO-2007147794-A1 | FURAN DERIVATIVES AND THEIR USE AS ANTIVIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007071434-A1 | ANTIVIRAL 2-CARBOXY-THIOPHENE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158025-A1 | GALACTOKINASE INHIBITORS | GALK1, GCK, GCKR | RAB9A 2719/4885NPC1 3021/4885GFER 2513/4885 |
| US-20090136448-A1 | Antiviral 2-Carboxy-Thiophene Compounds | EIF2AK2, HAVCR2, MAVS | RAB9A 1920/4885NPC1 1833/4885GFER 2833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.